October 11, 2016
1 min read
Save

FDA grants breakthrough designation to NiCord for bone marrow transplantation

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted breakthrough therapy designation to the novel graft modality NiCord for bone marrow transplantation in patients with hematological malignancies, according to the modality’s manufacturer.

NiCord (Gamida Cell) — an ex vivo expanded cell graft that utilizes NAM platform technology (Gamida Cell) to expand cells from the umbilical cord blood — is in development as an alternative to a bone marrow transplant for patients who cannot find a donor with fully-matched tissue.

The pilot and phase 1/phase 2 studies of NiCord in patients with hematologic malignancies demonstrated an improvement in time to neutrophil engraftment over cord blood transplantation.

In addition, NiCord showed fewer infections, reduced length of hospitalization, quicker platelet engraftment and improved non-relapse mortality when compared to unmanipulated cord blood transplantation.

“We are very pleased the FDA has recognized the potential of NiCord to address the unmet clinical need in bone marrow transplantation,” Yael Margolin, PhD, president and CEO of Gamida Cell, said in a press release. “The breakthrough therapy designation creates the foundation for a joint and concerted effort between the FDA and Gamida Cell to bring this important therapy faster to patients. We look forward to continuing our close cooperation with the FDA and other regulatory agencies to a positive conclusion as we prepare for commercialization.”